Trial Profile
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 (Brigimadlin) in Patients With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Brigimadlin (Primary)
- Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Glioblastoma; Liposarcoma; Non-small cell lung cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 20 Jan 2024 Results of pooled analysis from NCT03449381 and NCT03964233, for safety and efficacy, presented at the 2024 Gastrointestinal Cancers Symposium
- 14 Nov 2023 Planned number of patients changed from 204 to 269.
- 24 Oct 2023 Results (n=140; data cutoff date: Apr 2023) reporting safety and efficacy for all pts who received BI 907828 once every 3 weeks (Q3W) presented at the 48th European Society for Medical Oncology Congress